CBD shows promise for reducing Self-Injury in kids with severe developmental disorders
NCT ID NCT07564245
First seen May 08, 2026 · Last updated Jun 17, 2026 · Updated 8 times
Summary
This study tests whether cannabidiol (CBD) can reduce severe self-injuries like biting or head-hitting in children aged 5 to 17 with severe neurodevelopmental disorders. Researchers will give CBD to 21 participants and measure if the frequency of self-harm drops by at least 30% over 63 days. The goal is to find a safer treatment option for these challenging behaviors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURODEVELOPMENTAL DISORDERS WITH SEVERE SELF-INJURIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Necker Enfants malades
Paris, Île-de-France Region, 75015, France
Contact Email: •••••@•••••
-
Hôpital Pitié-Salpêtrière
Paris, Île-de-France Region, 75013, France
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.